| __timestamp | Amphastar Pharmaceuticals, Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 8185000 |
| Thursday, January 1, 2015 | 46974000 | 8871000 |
| Friday, January 1, 2016 | 47298000 | 9645000 |
| Sunday, January 1, 2017 | 50918000 | 12387000 |
| Monday, January 1, 2018 | 58044000 | 14381000 |
| Tuesday, January 1, 2019 | 63109000 | 19238000 |
| Wednesday, January 1, 2020 | 65157000 | 17425000 |
| Friday, January 1, 2021 | 68920000 | 23040000 |
| Saturday, January 1, 2022 | 66592000 | 25116000 |
| Sunday, January 1, 2023 | 80393000 | 51953000 |
Unleashing the power of data
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Amphastar Pharmaceuticals, Inc. and CymaBay Therapeutics, Inc. have shown contrasting approaches over the past decade. From 2014 to 2023, Amphastar's SG&A expenses grew by approximately 99%, peaking in 2023. In contrast, CymaBay's expenses surged by over 500% during the same period, indicating a more aggressive expansion strategy.
Amphastar's steady increase reflects a controlled growth strategy, maintaining an average annual increase of around 8%. Meanwhile, CymaBay's expenses, though initially lower, have escalated rapidly, suggesting significant investment in growth and development. This divergence highlights the strategic choices companies make in balancing cost management with growth ambitions. As investors and stakeholders evaluate these trends, understanding the nuances of SG&A management becomes essential for predicting future performance.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Insmed Incorporated vs CymaBay Therapeutics, Inc.
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.